Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Episodes
Mentioned books
Jan 15, 2026 • 22min
GI ASCO 2026 Highlights MATTERHORN, HERIZON-GEA-01, BREAKWATER, COMMIT – Dr. Rachna Shroff
We’re kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026.
We dived into the latest updates that will directly impact your clinical decisions, from new standards in perioperative therapy to revolutionary front-line regimens for metastatic disease.
Key topics covered in this episode:
● MATTERHORN update: Surgical outcomes & FLOT modifications with Durvalumab in resectable gastric/GEJ cancer
● HERIZON-GEA-01: Zanidatamab + chemo + Tislelizumab the new frontline standard for HER2+ gastric cancer
● BREAKWATER: Confirming Encorafenib + Cetuximab + chemo (FOLFOX or FOLFIRI) for BRAF V600E mCRC
● COMMIT: Chemo + Atezolizumab vs. Atezolizumab alone in MSI-H/dMMR metastatic colorectal cancer
Tune in for this dense, insightful recap and stay ahead of the curve.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don’t forget to subscribe for more expert analysis on treatment algorithms and major conference highlights!
#OncologyBrothers #GI26 #GastricCancer #ColorectalCancer #HER2 #BRAF #MSI #OncologyPodcast
Jan 11, 2026 • 14min
ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17, BRUIN CLL-313, SWOG-1826: Dr. Julie Vose
In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL).
Episode Highlights:
● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma
● CLL-17: comparison between continuous BTK inhibitors and fixed-duration venetoclax with obinutuzumab
● BRUIN CLL-313: insights into the non-covalent BTK inhibitor, pirtobrutinib, and its effectiveness in the frontline setting compared to traditional treatments
● S1826: a three-year update on the use of Nivolumab-AVD versus BV-AVD in advanced-stage Hodgkin's lymphoma, showcasing improved PFS and better tolerability
Join us as we unpack these practice-changing studies and discuss their implications for community oncologists.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more insights and highlights from oncology conferences!
#ASH25 #Oncology #Hematology #Lymphoma #CLL #CancerResearch
Jan 7, 2026 • 17min
ASH 2025 Leukemia Highlights PARADIGM, KOMET-007, ASC4FIRST, ASC2ESCALATE - Dr. Jorge Cortes
In this episode of the Oncology Brothers podcast, we dived into the key highlights from ASH 2025, focusing on advancements in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
We welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss key studies from the leukemia space, including the PARADIGM trial comparing Azacitidine plus Venetoclax to traditional 7 + 3 induction chemotherapy for fit patients with newly diagnosed AML. We explore the implications of these findings, the potential for hypomethylating agents in treatment regimens, and the evolving landscape of CML therapies, including the promising results from the ASK4FIRST/ASK2ESCALATE featuring Asciminib.
Key topics covered in this episode:
● The PARADIGM trial and its impact on AML treatment strategies
● Real-world evidence on shortened venetoclax dosing
● The role of menin inhibitors in combination therapies
● Patient-reported outcomes and quality of life with asciminib in CML
Tune in for an insightful discussion on the future of leukemia treatment and the importance of patient-centered care.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more updates on treatment algorithms, recent approvals, and conference highlights!
#OncologyBrothers #ASH2025 #ASH25 #AML #CML #Leukemia #Hematology
Jan 5, 2026 • 23min
HER2+ SABCS 2025 Highlights DESTINY Breast-05/Breast-11, HER2CLIMB-05, PATINA: Dr. Harold Burstein
Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive disease.
Special guest Dr. Harold Burstein from Dana-Farber Cancer Institute shared his insights on the evolving landscape of HER2-positive breast cancer treatment, including the importance of patient selection and the management of side effects like interstitial lung disease (ILD).
Tune in for a comprehensive recap of the latest data, treatment algorithms, and how these advancements are changing the lives of patients with HER2-positive breast cancer.
Don't forget to like, subscribe, and check out our other episodes for more updates on treatment options and conference highlights!
Topics Covered:
• DESTINY Breast-11 and its impact on neoadjuvant therapy
• Insights from DESTINY Breast-05 on adjuvant treatment for high-risk residual disease
• HER2CLIMB-05 trial findings and implications for metastatic disease
• The role of T-DXd with pertuzumab in frontline settings
• The PATINA trial and its significance for triple-positive metastatic breast cancer
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms, recent approvals, and conference highlights!
#SABCS2025 #HER2positive #DestinyTrials #OncologyBrothers #BreastCancer
Jan 3, 2026 • 25min
Triple Negative Breast Cancer SABCS 2025 Highlights: Dr. Rebecca Shatsky
In this episode of the Oncology Brothers podcast, we were joined by Dr. Rebecca Shatsky, a breast medical oncologist and director of the Inflammatory and Triple Negative Breast Cancer Program at UC San Diego. We dived into the latest findings from the SABCS 2025 conference, focusing on key studies related to triple negative breast cancer (TNBC).
Join us as we discussed:
* The RJBC 1501 study, which explored the role of carboplatin in high-risk early-stage TNBC and its impact on disease-free survival.
* Insights from the CITRIN study, which questions the carboplatin paradigm and highlights modern treatment approaches.
* The TBCRC-056 and OlympiaN trials, investigating the combination of PARP inhibitors and immunotherapy in patients with germline BRCA and PALB2 mutations.
We unpacked the implications of these studies for clinical practice, including the potential benefits and challenges of incorporating carboplatin and novel therapies into treatment regimens.
Tune in for an informative discussion that aims to keep you updated on the evolving landscape of breast cancer treatment!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights from the world of oncology!
#SABCS2025 #TNBC #PARPinhibitors #BRCAmutation #ChemoFree #OncologyBrothers #BreastCancer #SABCS25
Dec 31, 2025 • 20min
Enfortumab vedotin + Pembro FDA Approval in Muscle Invasive Bladder Cancer (MIBC): Dr. Thomas Powles
Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study.
We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study design, findings, and implications for patient care. Discover how this new standard of care is transforming treatment options, improving event-free survival, and overall survival rates for patients.
Key topics covered in this episode included:
• Overview of the Keynote-905/EV-303 study and its significance
• Comparison with previous studies like the NIAGARA trial
• Discussion on the side effects of EV Pembro and management strategies
• The role of ctDNA in guiding post-operative therapy
• Future directions in bladder cancer research and upcoming trials
Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more practice-changing updates in oncology!
#BladderCancer #Keynote905 #ADC #Immunotherapy #OncologyBrothers #GUOncology #MIBC
Dec 26, 2025 • 24min
Metastatic HR+ Breast Cancer SABCS 2025 Highlights: Dr. Hope Rugo
Dr. Hope Rugo, a leading breast medical oncologist from City of Hope, shares her expert insights on metastatic hormone receptor-positive breast cancer, highlighting key findings from the SABCS 2025 conference. She discusses the superiority of CDK4-6 inhibitors over chemotherapy, strategies for choosing effective treatments, and the significance of ongoing clinical trials like SERENA-6 and VIKTORIA-1. Dr. Rugo also addresses the implications of recent studies on antibody-drug conjugates, offering essential clinical tips for treatment selection and toxicity management.
Dec 22, 2025 • 16min
Early HR+ Disease SABCS 2025 Practice Changing/Informing Highlights: ALTTO, lidERA, NATALEE
Dr. Laura Huppert, an academic medical oncologist at UCLA, joins to unpack groundbreaking findings from the SABCS 2025 conference on early-stage hormone receptor-positive breast cancer. She delves into the ALTTO study, highlighting the advantage of aromatase inhibitors over tamoxifen. The discussion then moves to the lidERA study, spotlighting the potential of giredestrant in improving invasive disease-free survival. Finally, insights from the NATALEE trial showcase the enduring benefits of ribociclib across various patient subgroups, reshaping treatment strategies.
Dec 21, 2025 • 10min
Advancements and Challenges in Metastatic Colorectal Cancer Treatment
The podcast dives into the latest advances in treating metastatic colorectal cancer. Key discussions highlight the significance of next-generation sequencing and biomarker testing in treatment decisions. Second-line options like TAS-102, Regorafenib, and Fruquintinib are explored along with crucial clinical trial data. The conversation also covers managing side effects and improving patient quality of life. Insights from the STELLAR-303 study reveal new perspectives on immunotherapy, setting the stage for better treatment strategies.
Dec 19, 2025 • 25min
Clinical Implications of Testing HER2 and Targeted Therapies Approved - Dr. Komal Jhaveri
Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, shares her expertise on the significance of HER2 testing in metastatic hormone receptor positive breast cancer. She discusses groundbreaking findings from the DESTINY Breast-04 and -06 studies, exploring low and ultra-low HER2 expressions, and the implications for treatment options. Dr. Jhaveri highlights the importance of antibody-drug conjugates like T-DXd, while addressing management strategies for treatment-related toxicities, making this a must-listen for healthcare professionals.
